Skip to main content

Table 4 ROC models comparing influence of clinical variables determined at baseline visit on separation of the fibrosis and cirrhosis groups in the validation set

From: Increased sialylation of site specific O-glycoforms of hemopexin in liver disease

 

Cut-off pointa

Sensitivity (%)

Specificity (%)

AuROC

SE

95 % CI

AFP

11.6

50

79

0.65

0.153

(0.35, 0.95)

Platelet

163

80

50

0.63

0.134

(0.37, 0.89)

APRI

1.45

60

86

0.73

0.145

(0.44, 1.00)

FIB-4

2.60

80

71

0.74

0.144

(0.47, 1.00)

S-HPX

42.5

60

93

0.84

0.145

(0.53, 1.00)

  1. Samples were used in Fig. 4b
  2. aOptimal cut-off point was calculated based on fitted models from the discovery set